The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.

The CA125/MUC16 protein has been found to be a suppressor of humoral immunity, in particularly antibody-mediated humoral immunity. The generation of antagonists that can block its immune suppressive effects on antibodies may lead to enhanced therapeutic responses by antibodies that are negatively impacted by CA125/MUC16. In addition, it offers the ability to unlock humoral immune suppression of a patient's endogenous humoral response that may be suppressed by CA125/MUC16 suppression. CA125/MUC16 antagonists can be used to enhance humoral response of therapeutic antibodies and patients with CA125/MUC16-expressing diseases, including cancer.

Materials and methods for treating potentially chemoresistant tumors (e.g., using DNA-PKcs inhibitors and anti-B7-H1 antibodies) are provided herein.

The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens.

The present disclosure relates to novel DNA aptamers and use thereof. In particular, the present disclosure relates to DNA aptamers selected from a DNA library using Cell-SELEX to bind specifically to cancer cells. The DNA aptamers of the present disclosure selected and optimized for high binding affinity to cancer cells can be effectively used for the diagnosis of cancer as they have enhanced targeting efficiencies for target cells and tissues.

The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a breast cancer or a pancreatic cancer). More specifically, the invention concerns the treatment of patients having cancer for the therapeutic inhibition of cancer cell growth and metastasis with an anti-Cadherin 11 monoclonal antibody with specific monoclonal antibody clones 23C6 or 3H10.

Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens.

The present invention provides antibody drug conjugates (ADCs) of humanized anti-PVR (CD155) and use thereof in treating diseases, in particular cancer.

Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

Disclosed herein is a glycoengineered tumor cell or a glycoengineered tumor cell fragment for use in treatment and/or prevention of cancer, in particular cancerous neoplasms, in a subject. The glycoengineered tumor cell or tumor cell fragment includes a tumor cell surface including one or more carbohydrate antigen moieties. Furthermore, a pharmaceutical composition including such a cell or cell fragment, a method for producing such a glycoengineered tumor cell or tumor cell fragment and a method of treatment of a subject including the administration of such a glycoengineered tumor cell or glycoengineered tumor cell fragment to a subject is disclosed.